O Staphylococcus aureus é uma bactéria do grupo dos cocos gram-positivos que faz parte da microbiota humana, mas que pode provocar doenças que vão desde uma infecção simples, como espinhas e furúnculos, até as mais graves, como pneumonia, meningite, endocardite, síndrome do choque tóxico e septicemia, entre outras. Essa bactéria foi uma das primeiras a serem controladas com a descoberta dos antibióticos, mas, devido a sua enorme capacidade de adaptação e resistência, tornou-se uma das espécies de maior importância no quadro das infecções hospitalares e comunitárias. Neste artigo faremos uma revisão sobre esse agente infeccioso e as bases dos mecanismos das patologias por ele provocadas, de forma a ressaltar a necessidade de mantê-lo como alvo para o desenho de novos antibióticos. IntroduçãoO Staphylococcus aureus é uma bactéria esférica, do grupo dos cocos gram-positivos, freqüentemente encontrada na pele e nas fossas nasais de pessoas saudáveis. Entretanto pode provocar doenças, que vão desde uma simples infecção (espinhas, furúnculos e celulites) até infecções graves (pneumonia, meningite, endocardite, síndrome do choque tóxico, septicemia e outras). A implantação da antimicrobianoterapia, no início da década de 1930, com o emprego da sulfanilamida (descoberta por Gerard Domagk em 1932),

Lately several naturally occurring peptides presenting antimicrobial activity have been described in the literature. However, snake venoms, which are an enormous source of peptides, have not been fully explored for searching such molecules. The aim of this work is to review the basis of antimicrobial mechanisms revealing snake venom as a feasible source for searching an antibiotic prototype. Therefore, it includes (i) a description of the constituents of the snake venoms involved in their main biological effects during the envenomation process; (ii) examples of snake venom molecules of commercial use; (iii) mechanisms of action of known antibiotics; and (iv) how the microorganisms can be resistant to antibiotics. This review also shows that snake venoms are not totally unexplored sources for antibiotics and complementary and alternative medicine (CAM).

Vários derivados de 1,4-naftoquinonas contendo um grupo hidrazino como cadeia lateral foram sintetizados a partir do 3-diazo-naftaleno-1,2,4-triona e foram avaliados como potenciais agentes antimicrobianos. Os derivados naftoquinônicos 2--hidrazono]-malonato de etila mostraram maior atividade antibacteriana, ao nível de teste preliminar em disco, que o lapachol (1), uma 1,4-naftoquinona muito conhecida pelas suas variadas atividades biológicas. Estudo sobre a concentração mínima inibitória (MIC) para o Staphylococcus aureus mostrou que 2-[(3-hidroxi-1,4-dioxo-1,4-diidronaftaleno-2-il)-hidrazono]-malonato de etila tem uma atividade duas vezes maior que 1. Da mesma forma, o estudo da densidade ótica em cultura de S. aureus com esta substância mostrou uma atividade similar à da vancomicina na concentração de 2xMIC.Several 1,4-naphthoquinone derivatives having a hydrazino side chain were synthesized from 3-diazo-naphthalene-1,2,4-trione and tested as potential antimicrobial agents. These naphthoquinone derivatives 2-[N'-(1-acetyl-2-oxo-propylidene)-hydrazino]-3-hydroxy-[1,4]naphthoquinone, ethyl 2-[(3-hydroxy-1,4-dioxo-1,4-dihydro-naphthalen-2-yl)-hydrazono]-3-oxo-butyrate, t-butyl 2-[(3-hydroxy-1,4-dioxo-1,4-dihydro-naphthalen-2-yl)-hydrazono]-3-oxobutyrate, 3-hydroxy-2-[(di-O-isopropylidene-malonate)-hydrazino]-1,4-naphthoquinone, and diethyl 2-[(3-hydroxy-1,4-dioxo-1,4-dihydro-naphthalen-2-yl)-hydrazono]-malonate showed greater antibacterial activity at the level of the preliminary susceptibility testing in disk than lapachol (1), a well known 1,4-naphthoquinone which has several biological activities. Studies on the minimal inhibitory concentration (MIC) for Staphylococcus aureus showed that diethyl 2-[(3-hydroxy-1,4-dioxo-1,4-dihydro-naphthalen-2-yl)-hydrazono]-malonate has an activity twofold greater than 1. On the other hand, optical density measurement for S. aureus indicated that this compound has similar activity compared with vancomycin at 2xMIC.

Bacterial infections involving multidrug-resistant strains are one of the ten leading causes of death and an important health problem in need for new antibacterial sources and agents. Herein, we tested and compared four snake venoms (Agkistrodon rhodostoma, Bothrops jararaca, B. atrox and Lachesis muta) against 10 Gram-positive and Gram-negative drug-resistant clinical bacteria strains to identify them as new sources of potential antibacterial molecules. Our data revealed that, as efficient as some antibiotics currently on the market (minimal inhibitory concentration (MIC) = 1–32 μg mL−1), A. rhodostoma and B. atrox venoms were active against Staphylococcus epidermidis and Enterococcus faecalis (MIC = 4.5 μg mL−1), while B. jararaca inhibited S. aureus growth (MIC = 13 μg ml−1). As genomic and proteomic technologies are improving and developing rapidly, our results suggested that A. rhodostoma, B. atrox and B. jararaca venoms and glands are feasible sources for searching antimicrobial prototypes for future design new antibiotics against drug-resistant clinical bacteria. They also point to an additional perspective to fully identify the pharmacological potential of these venoms by using different techniques.

The minimal antibiotic concentration (MAC) is the lowest concentration of an antibacterial agent that produces a decrease of 1 log in the number of organisms/ml as compared with a control culture in drug-free medium. Various gram-negative bacilli and gram-positive cocci were grown in the presence of amikacin, gentamicin, tobramycin, ampicillin, amoxicillin, oxacillin, carbenicillin, ticarcillin, and cefamandole at concentrations varying from eight times the minimal inhibitory concentration (MIC) to 1/128 of the MIC. Colony forming units (cfu) were counted, the MIC was determined, and the MIC:MAC ratio, which indicates the magnitude of the effective range, was calculated. The MIC:MAC ratio appears to be characteristic for a given species and antibiotic. There is no relation between the MICs and the MIC:MAC ratios. The highest ratios were given by Proteus mirabilis with aminoglycosides (MIC:MAC mean, 29.2 with tobramycin), and the lowest ratios were given with beta-lactam antibiotics by Pseudomonas aeruginosa and Streptococcus faecalis (MIC:MAC means, 2.1 with carbenicillin and cefamandole, respectively).